Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics
Loading...
Date
2006
Journal Title
Journal ISSN
Volume Title
Publisher
ELSEVIER IRELAND LTD
Abstract
Background: After a study of ICA prevalence among relatives of Type-1 diabetics (DMI) in Santiago, Chile, parents of those who tested positive asked us to go on forward with an intervention study.
Methods: We had screened 1021 relatives, of which 30 had shown ICA >= 20 JDF units (2.9%). Among the 26/30 who participated in the intervention study, the baseline screening showed normal glucose tolerance in all, and the first-phase insulin response (FPIR) was normal in 24/26 individuals, which were randomized into Nicotinamide (n = 12; oral Nicotinamide, 1200 mg m(-2) day(-1)) and Placebo (n = 12) groups. The FPIRs and ICAs were monitored yearly. Compliance was monitored by urine Nicotinamide.
Results: The 1.5, 3.0 and 5-year life-table estimates of keeping the FPIR >= 10th centile were, for Nicotinamide group 100% in all time points, and for Placebo these were 90.0% (c.i. = 100-71.4), 72.0% (c.i. = 100-37.1) and 0.0% (c.i. = 0.0-0.0) (p = 0.0091). The 5-year life-table estimates of remaining diabetes-free were 100% for Nicotinamide and 62.5% for Placebo (p = 0.0483). No adverse effects were observed.
Conclusions: Oral Nicotinamide protected beta-cell function and prevented clinical disease in ICA-positive first-degree relatives of type-1 diabetes. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
Methods: We had screened 1021 relatives, of which 30 had shown ICA >= 20 JDF units (2.9%). Among the 26/30 who participated in the intervention study, the baseline screening showed normal glucose tolerance in all, and the first-phase insulin response (FPIR) was normal in 24/26 individuals, which were randomized into Nicotinamide (n = 12; oral Nicotinamide, 1200 mg m(-2) day(-1)) and Placebo (n = 12) groups. The FPIRs and ICAs were monitored yearly. Compliance was monitored by urine Nicotinamide.
Results: The 1.5, 3.0 and 5-year life-table estimates of keeping the FPIR >= 10th centile were, for Nicotinamide group 100% in all time points, and for Placebo these were 90.0% (c.i. = 100-71.4), 72.0% (c.i. = 100-37.1) and 0.0% (c.i. = 0.0-0.0) (p = 0.0091). The 5-year life-table estimates of remaining diabetes-free were 100% for Nicotinamide and 62.5% for Placebo (p = 0.0483). No adverse effects were observed.
Conclusions: Oral Nicotinamide protected beta-cell function and prevented clinical disease in ICA-positive first-degree relatives of type-1 diabetes. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
Description
Keywords
type-1 diabetes mellitus, nicotinamide, prevention, ISLET-CELL ANTIBODIES, INTERVENTION TRIAL ENDIT, INTRAVENOUS GLUCOSE, FOLLOW-UP, T-CELLS, CHILDREN, MELLITUS, PHASE, PROGRESSION, PREDICTION